This is with reference to the disclosure submitted by the Company on February 23, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Covidh Technologies has issued a revised disclosure correcting the name of the target company in its earlier filing. The company had signed a non-binding Letter of Intent (LOI) on February 23, 2026 with iSERA Biological Limited (initially wrongly named as iSERA Biological Private Limited) for the proposed acquisition of 100% of its equity shareholding. If completed, iSERA Biological Limited would become a wholly owned subsidiary of Covidh Technologies. The LOI is non-binding except for confidentiality, exclusivity, governing law, and costs clauses, and the deal remains subject to definitive agreements, due diligence, and regulatory, statutory, and shareholder approvals.
This is a correction to an earlier disclosure — no new information on deal terms or pricing has been added. For shareholders, the actual acquisition is still at an early, non-binding stage and subject to multiple approvals, so there is no immediate change to the company's business or financials until definitive agreements are signed.